128 related articles for article (PubMed ID: 19388543)
1. [Clinical significance of some genetic polymorphisms of cytochrome P-450: family CYP1 and subfamilies CYP2A, CYP2B and CYP2C].
Wojtczak A; Skretkowicz J
Pol Merkur Lekarski; 2009 Mar; 26(153):248-52. PubMed ID: 19388543
[TBL] [Abstract][Full Text] [Related]
2. [Clinical significance of some genetic polymorphisms of cytochrome P-450 subfamilies CYP2D, CYP2E and CYP3A--part II].
Wojtczak A; Skretkowicz J
Pol Merkur Lekarski; 2009 Aug; 27(158):166-9. PubMed ID: 19856888
[TBL] [Abstract][Full Text] [Related]
3. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
Zhou SF; Liu JP; Chowbay B
Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
[TBL] [Abstract][Full Text] [Related]
4. [Genetic polymorphisms of drug metabolizing enzymes].
Fujieda M; Yamazaki H; Kamataki T
Gan To Kagaku Ryoho; 2002 May; 29(5):663-8. PubMed ID: 12040668
[TBL] [Abstract][Full Text] [Related]
5. The enhancing effect of ethanol on the mutagenic activation of N-nitrosomethylbenzylamine by cytochrome P450 2A in the rat oesophagus.
Tatematsu K; Koide A; Morimura K; Fukushima S; Mori Y
Mutagenesis; 2013 Mar; 28(2):161-9. PubMed ID: 23325793
[TBL] [Abstract][Full Text] [Related]
6. Cytochromes P450 and cancer.
Kaminsky LS; Spivack SD
Mol Aspects Med; 1999; 20(1-2):70-84, 137. PubMed ID: 10575653
[No Abstract] [Full Text] [Related]
7. [Cancer pharmacogenetics: study of genetically determined variations on cancer susceptibility due to xenobiotic exposure].
Quiñones L; Lee K; Varela F N; Escala M; García K; Godoy L; Castro A; Soto J; Saavedra I; Cáceres D
Rev Med Chil; 2006 Apr; 134(4):499-515. PubMed ID: 16758088
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics: a molecular sophistication or a new clinical tool for cardiologists?
Dirckx C; Donati MB; Iacoviello L
Ital Heart J; 2000 Oct; 1(10):662-6. PubMed ID: 11061362
[TBL] [Abstract][Full Text] [Related]
9. Ah receptor, CYP1A1, CYP1A2 and CYP1B1 gene polymorphisms are not involved in the risk of recurrent pregnancy loss.
Saijo Y; Sata F; Yamada H; Suzuki K; Sasaki S; Kondo T; Gong YY; Kato EH; Shimada S; Morikawa M; Minakami H; Kishi R
Mol Hum Reprod; 2004 Oct; 10(10):729-33. PubMed ID: 15299091
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance.
Totah RA; Rettie AE
Clin Pharmacol Ther; 2005 May; 77(5):341-52. PubMed ID: 15900280
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of a dietary phytochemical 3,3'-diindolylmethane on the phenobarbital-induced hepatic CYP mRNA expression and CYP-catalyzed reactions in female rats.
Parkin DR; Lu Y; Bliss RL; Malejka-Giganti D
Food Chem Toxicol; 2008 Jul; 46(7):2451-8. PubMed ID: 18486294
[TBL] [Abstract][Full Text] [Related]
12. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
[TBL] [Abstract][Full Text] [Related]
13. Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer.
Suzuki S; Muroishi Y; Nakanishi I; Oda Y
J Gastroenterol; 2004; 39(3):220-30. PubMed ID: 15064998
[TBL] [Abstract][Full Text] [Related]
14. [Combined effects of genetic polymorphisms in cytochrome P450s and GSTM1 on lung cancer susceptibility].
Gu YF; Zhang ZD; Zhang SC; Zheng SH; Jia HY; Gu SX
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3064-8. PubMed ID: 18261353
[TBL] [Abstract][Full Text] [Related]
15. Expression and localization of the CYP2B subfamily predominantly in neurones of rat brain.
Rosenbrock H; Hagemeyer CE; Ditter M; Knoth R; Volk B
J Neurochem; 2001 Jan; 76(2):332-40. PubMed ID: 11208896
[TBL] [Abstract][Full Text] [Related]
16. Effects of tobacco smoke on the gene expression of the Cyp1a, Cyp2b, Cyp2e, and Cyp3a subfamilies in mouse liver and lung: relation to single strand breaks of DNA.
Villard PH; Seree EM; Re JL; De Meo M; Barra Y; Attolini L; Dumenil G; Catalin J; Durand A; Lacarelle B
Toxicol Appl Pharmacol; 1998 Feb; 148(2):195-204. PubMed ID: 9473526
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk.
Bozina N; Bradamante V; Lovrić M
Arh Hig Rada Toksikol; 2009 Jun; 60(2):217-42. PubMed ID: 19581216
[TBL] [Abstract][Full Text] [Related]
18. [Clinical significance of cytochrome P450 genetic polymorphism--part I. Enzymatic system of cytochrome P450 and cytochrome P450 1A2].
Duricová J; Grundmann M
Ceska Slov Farm; 2011 Jun; 60(3):110-5. PubMed ID: 21838140
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. III. Influence of CYP genetic polymorphism on population differentiation of drug metabolism phenotype.
Tomaszewski P; Kubiak-Tomaszewska G; Łukaszkiewicz J; Pachecka J
Acta Pol Pharm; 2008; 65(3):319-29. PubMed ID: 18646551
[TBL] [Abstract][Full Text] [Related]
20. CYP1A1, CYP3A5 and CYP3A7 polymorphisms and testicular cancer susceptibility.
Kristiansen W; Haugen TB; Witczak O; Andersen JM; Fosså SD; Aschim EL
Int J Androl; 2011 Feb; 34(1):77-83. PubMed ID: 20345875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
